FDA Review Statuses: Savara Molgramostim Review Ongoing; Capricor Receives Rejection
What happened
The FDA confirmed that the review of Savara Inc.'s inhaled drug, molgramostim, will not meet its goal date of November 22, 2026, and no new date has been set. The agency stated the review remains ongoing and did not issue a formal rejection letter. Separately, the FDA issued a rejection to Capricor Therapeutics for its cell therapy, deramiocel.
From techtimes.com
Why it matters
Regulatory decisions regarding new treatments directly impact market supply and demand for specific diseases. The rejection of Capricor's deramiocel and the delay in the molgramostim review affect the availability of treatments for autoimmune pulmonary alveolar proteinosis in the United States.
From techtimes.com
Who's involved
- FDARegulatory agency that reviewed the drug applications for Savara Inc. and Capricor Therapeutics
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- United States of AmericaSpeculative
The market for autoimmune pulmonary alveolar proteinosis treatments might see changes in demand due to the rejection of Capricor Therapeutics' deramiocel.
- FDASpeculative
Savara Inc.'s stock price could be affected by the uncertainty surrounding the molgramostim review.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Savara's US drug review delay may influence EMA's European decisionSavara's US drug review delay may influence EMA's European decisionPossible
- How could FDA review and rejection in rare disease drug development affect company?Regulatory uncertainty in rare disease drug development may increase risk for companies.Possible
- FDA's biologics review decisions may affect CBER's workloadFDA's handling of biologics applications may shift CBER's operational focusPossible
- How could FDA review and rejection of aPAP treatments affect United States of America?Increased uncertainty over aPAP treatments could prolong reliance on invasive care in the USPossible